Table 1.
Selected trials of daratumumab in multiple myeloma
| Clinical Trial | Phase | Setting | Treatment | ORR (%) | CR (%) | MRD neg (%) |
|---|---|---|---|---|---|---|
|
NCT 00574288 (GEN501) |
1/2 | RRMM | Monotherapy, dose-escalation | 36 | 4,7 | NA |
|
NCT 02316106 (SMM2001 - CENTAURUS) |
2 | SMM (intermediate-R, high-R) |
Monotherapy | 56,1 (intense arm) 53,7 (intermediate arm) 37,5 (short arm) |
5,0 10,0 0,0 |
NA |
|
NCT 01985126 (MMY2002 – SIRIUS) |
2 | RRMM | Monotherapy | 29,2 | 2,8 | NA |
| GEN501 + SIRIUS | 1/2 | RRMM | Monotherapy | 31,1 | 4,7 | NA |
|
NCT 01615029 (GEN503) |
1/2 | RRMM | Dara-Rd, dose escalation | 81 | 25,0 | 34,4 |
|
NCT 03158688 (CANDOR) |
3 | RRMM | Dara-Kd vs Kd | 84,3 vs 74,7 | 29,0 vs 10,0 | 14 vs 3 |
|
NCT 02874742 (MMY2004 – GRIFFIN) |
2 | NDMM eligible for HDT or ASCT |
Dara-RVd vs RVd | 99 vs 91,8 | 80 vs 61 | 51 vs 20 |
|
NCT 03357952 (MMY2036) |
multiphase | RRMM | Anti PD1-Dara | 44,4 | NA | NA |
|
NCT 02076009 (MMY3003 – POLLUX) |
3 | RRMM | Dara-Rd vs Rd | 92,9 vs 76,4 | 43,1 vs 19,2 | 22,4 vs 4,6 |
|
NCT 02136134 (MMY 3004 – CASTOR) |
3 | RRMM | Dara-Vd vs Vd | 85 vs 63 92 vs 74 (1 prior line treatment) |
30 vs 10 43 vs 15 |
14 vs 2 20 vs 3 |
|
NCT 02541383 (MMY3006 – CASSIOPEIA) |
3 | NDMM eligible for ASCT |
Dara-VTd vs VTd | 92,6 vs 89,9 | 39 vs 26 | 64 vs 44 |
|
NCT02195479 (MMY3007 - ALCYONE) |
3 | NDMM ineligible for HDT and ASCT |
Dara-VMP vs VMP | 90,9 vs 73,9 | 42,6 vs 24,4 | 22,3 vs 6,2 |
|
NCT 02252172 (MMY3008 – MAIA) |
3 | NDMM ineligible for HDT and ASCT |
Dara-Rd vs Rd | 92,9 vs 81.3 | 47,6 vs 24,9 | 24,2 vs 7,3 |
|
NCT 03412565 (MMY2040 – PLEIADES) |
2 | NDMM | Dara sc VMP vs Dara sc VRd vs Dara sc Rd |
89,6 97,0 93,8 |
47,8 16,5 38,5 |
16,4 n.a 15,4 |
|
NCT 03180736 (MMY3013 – APOLLO) |
3 | RRMM | Dara sc Pd vs Pd | 68,9 vs 46,4 | 25 vs 4 | 9 vs 2 |